

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/030075 A1

(51) International Patent Classification:

A61K 31/404 (2006.01) *A61K 31/40* (2006.01)
C07D 209/04 (2006.01) *A61K 31/403* (2006.01)
C07D 209/16 (2006.01)

(21) International Application Number:

PCT/US2024/040668

(22) International Filing Date:

02 August 2024 (02.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/530,653	03 August 2023 (03.08.2023)	US
18/368,099	14 September 2023 (14.09.2023)	US
18/368,124	14 September 2023 (14.09.2023)	US

(71) Applicant: **GILGAMESH PHARMACEUTICALS, INC.** [US/US]; 113 University Place, Suite 1019, New York, New York 10003 (US).

(72) Inventors: **KRUEGEL, Andrew Carry**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **LEONG, William**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **HE, Ya-meng**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **MACEACHERN, Lauren**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CRYSTALLINE HYDROCHLORIDE AND FUMARATE SALTS OF N-ETHYL-2- (5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE

(57) Abstract: The present disclosure relates to a crystalline salt selected from crystalline N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine fumarate and crystalline N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride, method of preparing them, and use thereof for treating mood disorders. In addition, the present disclosure relates to polymorphs of the aforementioned salts. Further, the present disclosure relates to an oil or amorphous N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, method of preparing the same and use thereof for treating mood disorders.

WO 2025/030075 A1